Digestive Diseases and Sciences

, Volume 62, Issue 3, pp 633–638 | Cite as

Circulating Bone Marrow-Derived CD45−/CD34+/CD133+/VEGF+ Endothelial Progenitor Cells in Adults with Crohn’s Disease

  • Doron BoltinEmail author
  • Zvi Kamenetsky
  • Tsachi Tsadok Perets
  • Yifat Snir
  • Boris Sapoznikov
  • Hemda Schmilovitz-Weiss
  • Jacob Nadav Ablin
  • Ram Dickman
  • Yaron Niv
Original Article



Circulating endothelial progenitor cells (EPCs) are bone marrow-derived stem cells able to migrate to sites of damaged endothelium and differentiate into endothelial cells. Altered EPC level and function have been described in various inflammatory diseases and have been shown to augment vasculogenesis in murine models. Previous studies of EPC in the context of Crohn’s disease (CD) have yielded conflicting results.


To determine whether the circulating levels of EPCs are changed in the context of CD.


CD patients and healthy controls were recruited. Disease activity was assessed by CDAI. Peripheral blood mononuclear cells were isolated and EPC numbers evaluated by FACS analysis using anti-CD34, anti-VEGF receptor-2, anti-CD133, and anti-CD45 markers.


Eighty-three subjects, including 32 CD patients and 51 controls were recruited, including 19 (59.4 %) and 23 (45 %) males (p = 0.26), aged 34.8 ± 14.9 and 43.3 ± 18.5 years (p = 0.64), in cases and controls, respectively. Mean CDAI was 147 ± 97, disease duration was 12.7 ± 11.1 years, and 28 (87.5 %) were receiving biologics for a mean duration of 21.7 ± 16.8 months. The mean level of peripheral EPCs in CD patients was 0.050 ± 0.086 percent and 0.007 ± 0.013 % in controls (p < 0.01). There was no significant correlation between EPC levels and age (r = −0.13, p = 0.47), CDAI (r = −0.26, p = 0.15), disease duration (r = −0.04, p = 0.84), or duration of treatment with biologics (r = 0.004, p = 0.99).


EPCs are elevated in patients with CD. Further studies are needed to examine the function of EPCs and their possible role as a marker of disease severity or therapeutic response.


Endothelial progenitor cell Crohn’s disease Inflammatory bowel disease Stem cell Bone marrow 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407.CrossRefPubMedGoogle Scholar
  2. 2.
    Ablin JN, Boguslavski V, Aloush V, et al. Enhanced adhesive properties of endothelial progenitor cells (EPCs) in patients with SLE. Rheumatol Int. 2011;31:773–778.CrossRefPubMedGoogle Scholar
  3. 3.
    Ablin JN, Boguslavski V, Aloush V, et al. Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 2006;79:2364–2369.CrossRefPubMedGoogle Scholar
  4. 4.
    Závada J, Kideryová L, et al. Circulating endothelial progenitor cells in patients with ANCA-associated vasculitis. Kidney Blood Press Res. 2008;31:247–254.CrossRefPubMedGoogle Scholar
  5. 5.
    Povsic TJ, Junge C, Nada A, et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013;165:854.e2–861.e2.CrossRefGoogle Scholar
  6. 6.
    Losordo DW, Kibbe MR, Mendelsohn F, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv. 2012;5:821–830.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Garolla A, D’Incà R, Checchin D, et al. Reduced endothelial progenitor cell number and function in inflammatory bowel disease: a possible link to the pathogenesis. Am J Gastroenterol. 2009;104:2500–2507.CrossRefPubMedGoogle Scholar
  8. 8.
    Marlicz W, Zuba-Surma E, Kucia M, Blogowski W, Starzynska T, Ratajczak MZ. Various types of stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients with Crohn’s disease. Inflamm Bowel Dis. 2012;18:1711–1722.CrossRefPubMedGoogle Scholar
  9. 9.
    Masuda J, Mitsuyama K, Yamasaki H, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with ulcerative colitis. Int J Mol Med. 2007;19:221–228.PubMedGoogle Scholar
  10. 10.
    Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease. Blood. 2010;116:6123–6132.CrossRefPubMedGoogle Scholar
  11. 11.
    Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease. JAMA. 2015;314:2524.CrossRefPubMedGoogle Scholar
  12. 12.
    Griffin MD, Elliman SJ, Cahill E, English K, Ceredig R, Ritter T. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? Stem Cells. 2013;31:2033–2041.CrossRefPubMedGoogle Scholar
  13. 13.
    Wood JA, Colletti E, Mead LE, et al. Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model. Hepatology. 2012;56:1086–1096.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600.CrossRefPubMedGoogle Scholar
  15. 15.
    de Toni L, Di Nisio A, Magagna S, et al. Altered chemokine signalling in endothelial progenitor cells from acute ulcerative colitis patients. Gastroenterol Res Pract. 2015;2015:843980.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Ratajczak MZ, Lee H, Wysoczynski M, et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia. 2010;24:976–985.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tanaka H, Arimura Y, Yabana T, et al. Myogenic lineage differentiated mesenchymal stem cells enhance recovery from dextran sulfate sodium-induced colitis in the rat. J Gastroenterol. 2011;46:143–152.CrossRefPubMedGoogle Scholar
  18. 18.
    Ando Y, Inaba M, Sakaguchi Y, et al. Subcutaneous adipose tissue-derived stem cells facilitate colonic mucosal recovery from 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats. Inflamm Bowel Dis. 2008;14:826–838.CrossRefPubMedGoogle Scholar
  19. 19.
    González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136:978–989.CrossRefPubMedGoogle Scholar
  20. 20.
    Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79–86.CrossRefPubMedGoogle Scholar
  21. 21.
    García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416–1423.CrossRefPubMedGoogle Scholar
  22. 22.
    Duijvestein M, Vos ACW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease. Gut. 2010;59:1662–1669.CrossRefPubMedGoogle Scholar
  23. 23.
    Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis. 2012;27:595–600.CrossRefPubMedGoogle Scholar
  24. 24.
    Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn’s disease. N Engl J Med. 2005;352:2193–2201.CrossRefPubMedGoogle Scholar
  25. 25.
    Case J, Mead Le, Bessler WK, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007;35:1109–1118.CrossRefPubMedGoogle Scholar
  26. 26.
    Gehling UM, Ergün S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000;95:3106–3112.PubMedGoogle Scholar
  27. 27.
    Masuda H, Alev C, Akimaru H, et al. Methodological development of a clonogenic assay to determine endothelial progenitor cell potential. Circ Res. 2011;109:20–37.CrossRefPubMedGoogle Scholar
  28. 28.
    Ingram DA. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood. 2005;106:1525–1531.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Doron Boltin
    • 1
    • 5
    Email author
  • Zvi Kamenetsky
    • 2
  • Tsachi Tsadok Perets
    • 3
  • Yifat Snir
    • 1
  • Boris Sapoznikov
    • 2
  • Hemda Schmilovitz-Weiss
    • 2
    • 5
  • Jacob Nadav Ablin
    • 4
    • 5
  • Ram Dickman
    • 1
    • 5
  • Yaron Niv
    • 1
    • 5
  1. 1.Division of GastroenterologyRabin Medical CenterPetah TikvaIsrael
  2. 2.Department of GastroenterologyRabin Medical CenterPetah TikvaIsrael
  3. 3.Gastroenterology Laboratory, Department of GastroenterologyRabin Medical CenterPetah TikvaIsrael
  4. 4.Department of RheumatologyTel Aviv Sourasky Medical CenterTel AvivIsrael
  5. 5.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations